Novartis (NVS) announced its mid-term guidance to 2025-2030 of a sales CAGR of 5-6% cc. The company noted that the updated outlook follows upgrade of 2024-2029 guidance to 6% cc. Also, the peak sales guidance was upgraded for Kisqali and Scemblix: Kisqali raised from $8 billion plus to $10 billion plus; Scemblix raised from $3 billion plus to $4 billion plus. Novartis expects 15 plus potentially submission-enabling readouts over the next two years.
Novartis said its delivered a core operating income margin of 41.2% in the first nine months of 2025 - two years ahead of plan - and expects to return to 40% plus margins by 2029, after absorbing 1-2 percentage points of dilution from the planned acquisition of Avidity Biosciences, which is expected to close in the first half of 2026.
Vas Narasimhan, CEO of Novartis, said: "Over the past two years, we have executed more than 30 strategic deals, bolstering our pipeline and strengthening the outlook of the business in the mid-2030s and beyond."
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.